Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
By Guest Contributor | November 7, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
By Katie Koziara | November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....
Read More
5 Ways to improve ICER’s value assessment framework
By Lauren Neves | June 20, 2019
The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...
Read More
Assessing value top of mind at ISPOR 2019
By Samantha Dougherty | June 5, 2019
As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...
Read More
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
By Katie Koziara | October 2, 2018
Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access...
Read More
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
By Lauren Neves | September 19, 2018
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...
Read More
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
By Guest Contributor | September 6, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Number of value-based contracts continues to rise
By Michelle Drozd | August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...
Read More
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
By Randy Burkholder | July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?
Read More
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
By Holly Campbell | July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
